Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00496301
Other study ID # SOGUG-02-06
Secondary ID
Status Completed
Phase Phase 2
First received July 3, 2007
Last updated January 13, 2009
Start date November 2006
Est. completion date December 2008

Study information

Verified date January 2009
Source Spanish Oncology Genito-Urinary Group
Contact n/a
Is FDA regulated No
Health authority Spain: Spanish Agency of Medicines
Study type Interventional

Clinical Trial Summary

Main Objective:

To evaluate progression-free survival in patients with unresectable renal cell carcinoma (RCC) treated with a combination of gemcitabine, capecitabine, and sorafenib.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2008
Est. primary completion date April 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must give their written informed consent before any procedure related to the study is performed; therefore, it must be given at the selection visit. The patient must be informed that he has the right to withdraw from the study at any time, without any kind of prejudice.

- Patients with renal clear cell carcinoma (RCC), unresectable and/or metastatic, histologically or cytologically documented (excluding the less common subtypes).

- Patients must not be candidates for any immunotherapeutic treatment, according to the response predictive factors, or must be intolerant to immunotherapeutic treatment.

- Patients classified as having median or low risk, according to Motzer's scoring.

- Patients (men or women) with ages equal or superior to 18 years old.

- ECOG = 1.

- Assessable or measurable disease.

- Patients with adequate haematological function, defined as:

- Neutrophils = 1.5 x 10^9/L

- Blood platelets = 100 x 10^9/L

- Haemoglobin = 10 g/dl

- Patients with adequate hepatic, renal, medullar and coagulation function, according to the following criteria:

- Total bilirubin < 1.5 times the superior limit of normality

- ALT and AST < 2.5 times the superior limit of normality (< 5 times the superior limit of normality in case of liver failure due to cancer)

- Amylase and lipase < 1.5 times the superior limit of normality

- Serum creatinine < 2 times the superior limit of normality

- TP or INR and TTP < 1.5 times the superior limit of normality. If patient is receiving anticoagulants, strict monitoring will be carried out, with evaluations on a weekly basis, at least, until the INR is stable, referring to a determination previous to dose administration, according to local standard care.

- Patients with a life expectancy superior to 12 weeks, at least.

- Patients may have received radiotherapy; however, this must not be the only target lesion.

- Patients from both sexes must use adequate contraceptive methods (oral or injectable contraceptives, intrauterine device, condom, sterilization) whilst participating in the protocol. After the retreat of treatment with BAY 43-9006, the contraceptive methods must be used for 4 weeks in women and for 3 months in men.

- Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions while on study

Exclusion Criteria:

- Patients who do not give their written informed consent to participate in the study.

- Patients with less common RCC subtypes, such as pure papillary cell tumours, Bellini carcinoma, medullary carcinoma or the oncocytic chromophobes and sarcomatoid variants, will be excluded from the study.

- Patients that have received previous treatment with chemotherapy or that had tumours that evolved during or after immunotherapy treatment.

- Patients that, due to their characteristics, may obtain a potential benefit from immunotherapy treatment.

- Patients that have received previous anti-angiogenic treatment.

- High-risk patients according to Motzer's classification.

- Concomitant treatment with another chemotherapy or immunotherapy.

- Arterial uncontrolled hypertension, which is defined as a systolic arterial pressure value > 150 mmHg or diastolic arterial pressure value > 90 mmHg, despite adequate medical treatment.

- Patients with a primary cancer diagnosis different from RCC, except in situ cervical carcinoma, baseline cellular carcinomas or superficial bladder tumours, prostate cancer pT1 gleason < 6 or other malign tumours which have received curative treatment > 5 years previous to the inclusion in this study.

- Cardiac arrhythmia antecedents, that require treatment with anti-arrhythmics (except for beta-blockers or digoxin), symptomatic coronary disease or ischemia (myocardial infarction in the previous 6 months) or congestive cardiac insufficiency > New York Heart Association (NYHA) class II

- Patients with active bacterial or fungal infectious processes, which are considered severe from the clinical point of view (= Common Terminology Criteria from the National Cancer Institute [CTC from NCI] grade 2, version 3)

- Patients that present previously known positive serology for HIV or chronic hepatitis B or C.

- Antecedents of organ allograft.

- Meningeal carcinomatosis or symptomatic uncontrolled cerebral disease.

- Patients with epileptic disorders that require medication (such as antiepileptics).

- All unstable conditions that could put the patient's security and/or his study accomplishment in danger.

- Abuse of substances, clinical conditions, psychological or social, that may interfere with the patient's participation in the study or with the evaluation of the study's results.

- Patients that present any contraindication or allergy to the study's investigational product.

- Patients that are participating or that have participated in any clinical trial in the 4 weeks previous to inclusion.

- Pregnant or breastfeeding women. Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication. Both men and women included in the study must use an adequate contraceptive method.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Gemcitabine, Capecitabine and Sorafenib (6 cycles)
Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21

Locations

Country Name City State
Spain Hospital del Mar Barcelona
Spain Hospital Vall d´Hebron Barcelona
Spain Hospital de Basurto Bilbao
Spain Hospital Santiago de Compostela Coruña
Spain Hospital Josep Trueta Gerona
Spain Hospital Juan Ramón Jiménez Huelva
Spain Hospital Clínico Virgen de la Victoria Málaga
Spain Clínica Universitaria de Navarra Pamplona
Spain Hospital Virgen Macarena Sevilla
Spain Hospital Xeral Cies Vigo

Sponsors (1)

Lead Sponsor Collaborator
Spanish Oncology Genito-Urinary Group

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival every 3 cycles and every two months in patients with "sorafenib" administered as monotherapy No
Secondary security profile every 3 cycles and every two months in patients with "sorafenib" administered as monotherapy Yes
Secondary Objective response index (CR/PR) and tumor growth control (CR/PR/SD) every three cycles and every two months in patients with "Sorafenib" treated as single agent No
Secondary Duration of response every three cycles and every two months in patients with "Sorafenib" treated as single agent No
Secondary Global survival At last contact date or death date No
Secondary Time to progression every three cycles and every two months in patients with "Sorafenib" treated as single agent No
See also
  Status Clinical Trial Phase
Completed NCT02248389 - Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses Phase 1
Completed NCT03900364 - a Prospective Trial Comparing Robot-assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy N/A
Completed NCT00158782 - Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients Phase 1
Completed NCT03109015 - Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing Phase 2
Completed NCT00363194 - A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients Phase 1
Completed NCT01012011 - Regulatory Post Marketing Surveillance Study on Nexavar® N/A
Completed NCT00842790 - Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging N/A
Completed NCT00529802 - Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer Phase 2
Completed NCT00356460 - Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma Phase 1
Completed NCT00387764 - Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Phase 3
Completed NCT00338884 - Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer Phase 2
Completed NCT00095186 - Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma Phase 2
Completed NCT00079612 - Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer Phase 2
Completed NCT00043368 - PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) Phase 2
Active, not recruiting NCT04489771 - A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) Phase 2
Completed NCT00516672 - Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors Phase 1
Withdrawn NCT05104905 - A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma Phase 1/Phase 2
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Withdrawn NCT03111901 - Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer Phase 1/Phase 2
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1